202 results on '"Willrich, Maria Alice V."'
Search Results
2. Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation
3. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
4. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
5. The VALIDity of laboratory developed tests: Leave it to the experts?
6. Characterizing M-protein light chain glycosylation via mass spectrometry
7. CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis
8. Cerebrospinal fluid kappa free light chains in patients with tumefactive demyelination.
9. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study
10. Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma
11. New-Onset Gait Difficulty With Kappa Free Light Chains in Cerebrospinal Fluid
12. Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains.
13. Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays
14. Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab
15. List of contributors
16. The complement system
17. A universal reference interval for serum immunoglobulins free light chains may be outdated
18. Analysis of Tryptic Peptides from Therapeutic Monoclonal Antibodies Using LC-MS/MS
19. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
20. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
21. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement
22. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
23. The Complement Alternative Pathway and Preeclampsia
24. Mo1522: MULTICENTER REAL-WORLD EXPERIENCE OF USTEKINUMAB TROUGH LEVELS AND ANTIBODIES IN CROHN’S DISEASE MAINTENANCE THERAPY
25. sj-pdf-6-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
26. sj-pdf-2-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
27. sj-pdf-19-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
28. sj-pdf-8-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
29. sj-pdf-9-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
30. sj-pdf-7-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
31. sj-pdf-4-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
32. sj-pdf-3-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
33. sj-pdf-5-msj-10.1177_13524585221134213 – Supplemental material for Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis
34. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.
35. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis.
36. Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation
37. Quantitative Alterations in Complement Alternative Pathway and Related Genetic Analysis in Severe Phenotype Preeclampsia
38. A Case of Unexpected Hyperglycemia
39. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
40. Complement testing in the clinical laboratory
41. Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals
42. CYP3A5⁎3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia
43. Chapter 23 - The complement system
44. A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders
45. Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review
46. MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients
47. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study
48. Performance of perpendicular drop versus tangent skimming gating of M-protein in proficiency testing challenges
49. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease
50. Assessment of complement interference in anti-Müllerian hormone immunoassays
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.